QuidelOrtho Corp(QDEL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,563 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
QDEL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for QuidelOrtho Corp (QDEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QDEL at 28.2/100 on a 32-signal composite quality model, placing it at rank #2,563 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (11.6) and balance sheet strength (12.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), QuidelOrtho Corp reports quarterly revenue of $630.9M, net income of $-92.9M, free cash flow of $-136.1M. Top institutional holders of QDEL by reported 13-F value include BlackRock, FMR, Newtyn Management, based on the most recent SEC filings. QDEL trades on the Nasdaq exchange and files with the SEC under CIK 1906324. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QDEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for QuidelOrtho Corp directly from SEC EDGAR. QuidelOrtho Corp's 13F Pro composite quality score has ranged between 25 and 71 since 2023, currently 28.2 — a declining long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$630.9M
Net Income
Q2 2026
$-92.9M
Free Cash Flow
Q2 2026
$-136.1M
ROIC
Q2 2026
-1.7%
D/E Ratio
Q2 2026
1.83
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-1.9% YoYNet Income
+44.8% YoYOperating Income
+53.1% YoYEPS (Diluted)
+45.4% YoYTotal Assets
-10.2% YoYTotal Debt
-3.7% YoYOp. Cash Flow
+26.7% YoYFree Cash Flow
+26.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.73B -1.9% | $2.78B -7.2% | $3.00B -8.2% | $3.27B +92.3% | $1.70B +2.2% | $1.66B |
| Net Income | $-1.13B +44.8% | $-2.05B -20216.8% | $-10.1M -101.8% | $548.7M -22.1% | $704.2M -13.1% | $810.3M |
| Operating Income | $-919.2M +53.1% | $-1.96B -1509.7% | $139.1M -83.5% | $843.7M -6.9% | $906.0M -14.6% | $1.06B |
| EPS (Diluted) | $-16.69 +45.4% | $-30.54 -20260.0% | $-0.15 -101.6% | $9.56 -41.8% | $16.43 -11.7% | $18.60 |
| Total Assets | $5.77B -10.2% | $6.42B -25.0% | $8.56B -3.3% | $8.86B +264.4% | $2.43B | — |
| Total Debt | $3.05B -3.7% | $3.17B +17.4% | $2.70B -11.8% | $3.06B +235584.6% | $1.3M | — |
| Operating Cash Flow | $105.2M +26.7% | $83.0M -70.4% | $280.2M -68.3% | $885.3M +9.9% | $805.9M +28.0% | $629.7M |
| Free Cash Flow | $-83.0M +26.0% | $-112.1M -258.1% | $70.9M -90.5% | $744.4M +45.1% | $513.1M -9.2% | $564.8M |
Get alerted when QDEL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for QuidelOrtho Corp including:
Top Institutional Holders of QDEL
BlackRock, Inc.
$196.2M11,202,523 shFMR LLC
$129.0M7,363,696 shNewtyn Management, LLC
$116.0M6,625,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$72.4M4,135,464 shNeuberger Berman Group LLC
$62.1M3,534,619 shInvesco Ltd.
$60.8M3,473,432 shAMERICAN CENTURY COMPANIES INC
$57.9M3,307,079 shRubric Capital Management LP
$57.9M3,306,281 shVANGUARD CAPITAL MANAGEMENT LLC
$53.8M3,070,054 shSTATE STREET CORP
$52.2M2,978,639 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $196.2M | 11,202,523 |
| FMR LLC | $129.0M | 7,363,696 |
| Newtyn Management, LLC | $116.0M | 6,625,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $72.4M | 4,135,464 |
| Neuberger Berman Group LLC | $62.1M | 3,534,619 |
| Invesco Ltd. | $60.8M | 3,473,432 |
| AMERICAN CENTURY COMPANIES INC | $57.9M | 3,307,079 |
| Rubric Capital Management LP | $57.9M | 3,306,281 |
| VANGUARD CAPITAL MANAGEMENT LLC | $53.8M | 3,070,054 |
| STATE STREET CORP | $52.2M | 2,978,639 |
Companies Similar to QDEL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PERRIGO Co plc
Enovis CORP
Orthofix Medical Inc.
AdaptHealth Corp.
INTEGRA LIFESCIENCES HOLDINGS CORP
NOVAVAX INC
DENTSPLY SIRONA Inc.
AVANOS MEDICAL, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put QDEL on your watchlist
Track score changes the day QuidelOrtho Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is QDEL a good stock to buy?
13F Pro's AI-powered analysis of QuidelOrtho Corp (QDEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QDEL are available on the QDEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. QDEL is classified as a small company.
Which hedge funds own QDEL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QDEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of QuidelOrtho Corp's investment landscape.